Researchers from University of Georgia in the US also noted that there was a big spike in 2013, the year in which Jolie revealed she carries a mutation.
A breast cancer (BRCA) gene test is a blood test to check for mutations in genes called BRCA1 and BRCA2. This test predict the risk of getting breast cancer and ovarian cancer.
"Appropriate use of BRCA testing would lead to reduction in avoidable cancer mortalities and morbidities," Chen said.
Women with hereditary BRCA gene mutations have a 45 to 65 per cent risk of developing breast cancer before age 70, compared to seven per cent in the general population, according to the US National Cancer Institute.
More From This Section
The study, published in the journal Genetics in Medicine analysed testing rates, payment to the provider, and out-of- pocket costs for patients from 2003 to 2014, and compared findings to reported revenue from Myriad Genetics, the only provider of the test until 2013.
That same year Hollywood actress Angelina Jolie published an op-ed in The New York Times promoting BRCA gene testing and the Supreme Court struck down the patent on BRCA gene testing, researchers said.
"This could provide insights on the impact of the policy changes and the media coverage of celebrity endorsement," said Chen.
Though it may be tempting to connect the whirlwind of media coverage surrounding Jolie's decision to have a double mastectomy following a positive BRCA test, the available data cannot point to which event had a greater impact, researchers said.
"In a companion study, we did examine whether women had follow-up surgical procedures and found an urban and rural disparity in the follow-up rates," said Chen.
"Women residing in urban areas consistently had a higher rates of follow-up surgical procedures than those in rural areas, though the gap is narrowing," Chen added
As genetic testing becomes more accessible, potential for individuals to make more informed decisions about their health, researchers said.